<DOC>
	<DOCNO>NCT02838472</DOCNO>
	<brief_summary>Nicotinamide nucleotide transhydrogenase ( NNT ) mutation cause glucocorticoid mineralocorticoid deficiency decrease detoxification reactive oxygen specie ( ROS ) adrenocortical cell . Ascorbic acid well know high antioxidant activity due neutralization free radical reactive oxygen specie . Preliminary result NNT_p.G200S homozygous fibroblast ' treatment 10 micro molar L-ascorbic acid show significant improvement mitochondrial morphology ROS content . The aim study figure ascorbic acid treatment improve phenotype NNT patient reduce ROS adrenocortical cell prevent apoptosis .</brief_summary>
	<brief_title>Ascorbic Acid Treatment Congenital Glucocorticoids Mineralocorticoids Deficiency Due NNT Mutation</brief_title>
	<detailed_description>Most case familial glucocorticoid mineralocorticoid deficiency cause mutation interrupt steroidogenesis 21- hydroxylase deficiency . Recently , nicotinamide nucleotide transhydrogenase ( NNT ) mutation find cause isolated glucocorticoid deficiency combine mineralocorticoid glucocorticoid deficiency decrease detoxification reactive oxygen specie ( ROS ) adrenocortical cell . NNT mutation mouse cause also glucose intolerance . Ascorbic acid essential water-soluble vitamin excellent reduce property , well know high antioxidant activity due neutralization free radical reactive oxygen specie . This vitamin act first line defense oxidative stress human body . Ascorbic acid treatment variant disease ( e.g . - cancer , type 2 diabetes , anxiety , depression , asthma cardiovascular disease ) meticulously study major adverse effect . In previous study , investigator demonstrate high ROS level , low ATP content change mitochondrial morphology NNT_p.G200S homozygous fibroblast compare control fibroblast . Preliminary result NNT_p.G200S homozygous fibroblast ' treatment 10 micro molar L-ascorbic acid show significant improvement mitochondrial morphology ROS content . The aim study figure ascorbic acid treatment improve phenotype NNT patient reduce ROS adrenocortical cell prevent apoptosis . During study NNT_p.G200S homozygous patient ( no.-3 ) hospitalise ACTH OGTT test start ascorbic acid treatment dose 75-80 % upper limit allowance accord IOM . ACTH OGTT repeat 6 month later assess improvement glucocorticoid production insulin resistance .</detailed_description>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>NNT mutation homozygous patient glucocorticoid deficiency</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>